JP4404352B2 - Skin preparation for summer - Google Patents

Description

  The present invention relates to an external preparation for skin, and more particularly to an external preparation for skin suitable for quasi drugs.

  Ascorbic acid, ascorbic acid phosphate ester, ascorbic acid-2-glucoside or a salt thereof is mainly used in the field of quasi drugs as an extremely safe melanin production inhibitor in the cosmetics field. ing. (For example, refer nonpatent literature 1) However, these main mechanisms are based on an ascorbic acid structure, and the medicinal effect of ascorbic acid has become the upper limit. Certainly, ascorbic acid is a whitening agent with a long history of use, and its effectiveness is well known, but it is also certain that there are many pigment abnormalities that cannot be handled by ascorbic acid. For example, ascorbic acids are said to be less effective against pigmentation that occurs following inflammation. On the other hand, in the field of whitening agents, for example, placenta extract such as BSE that cannot be denied, carcinogenic concerns, and kojic acid, which is restricted in use, is entangled with safety issues. Therefore, it is recognized that it is meaningful to enhance the whitening action of ascorbic acid having excellent safety. Against this background, attempts have been made to enhance the whitening action of ascorbic acids by combining various herbal extracts and ascorbic acids. (For example, see Patent Document 1, Patent Document 2, Patent Document 3, and Patent Document 4) However, even with these techniques, the whitening effect of ascorbic acid cannot be sufficiently enhanced. Also known is a combination of a plant extract and ascorbic acid which can be a base source of centauridine which is an essential component of the present invention. (For example, refer to Patent Document 5, Patent Document 6, and Patent Document 7) However, the blending amount of the extract disclosed in these techniques cannot contain 0.001 to 1% by mass of center ureidine. Therefore, even such a technique cannot sufficiently enhance the whitening effect of ascorbic acid. Centaureidine is a compound known in the literature and is already known to be contained in plants of various asteraceae plants such as cornflower. (For example, see Non-Patent Document 2 and Non-Patent Document 3)

  Accordingly, there is no known skin external preparation containing 1) ascorbic acid and / or a derivative thereof, and 2) 0.001 to 1% by mass of centaureidine and / or a salt thereof. It is not known that the melanin production inhibitory effect of ascorbic acids is remarkably enhanced.

Japanese Patent Laid-Open No. 2003-300858 JP 2003-160461 A JP 2003-95951 A JP 2004-75764 A JP 2002-128682 A JP 2002-60336 A JP 2002-128650 A Supervised by Katsuyuki Takeda et al. “Usefulness of Cosmetics” published by the Pharmaceutical Affairs Daily, March 31, 2001 Katerina V. et.al., Biomed. Papers, 147 (2), 119-130, 2003 Frank R. Stermitz et.al., Phytochemistry64 (2003), 493-497

  The present invention has been made under such circumstances, and an object of the present invention is to provide a technique for sufficiently enhancing the melanin production inhibitory effect of ascorbic acids.

In view of such a situation, the present inventors have sought for a technique for sufficiently enhancing the melanin production inhibitory effect of ascorbic acids, and as a result of intensive research efforts, as a result, centaureidine and / or its salt 0.001 to 0.001 It was found that such an effect can be obtained by coexisting 1% by mass, and the present invention has been completed. That is, this invention relates to the technique shown below.
(1) A skin external preparation characterized by containing 1) ascorbic acid and / or a derivative thereof, and 2) 0.001 to 1% by mass of centerureidine and / or a salt thereof.
(2) The ascorbic acid and / or salt thereof is one or more selected from ascorbic acid phosphate ester, ascorbic acid-2-glucoside and a salt thereof, (1 ) External preparation for skin.
(3) Centaureidine is a liquid-liquid extract of an alcoholic extract of an Asteraceae plant with ethyl acetate and water, and the ethyl acetate phase is concentrated, followed by fractional purification by column chromatography using silica gel as a carrier. The external preparation for skin according to (1) or (2), wherein the external preparation is derived from a product.
(4) The Asteraceae plants include Yarrow (Achilea millefolium), Cornflower (Centaurea cyanus), Tansy (Tanacetum parthenium), Russian cornflower (Acroptilon repens), Yacon (Smallanthus sonchifolius), Maca (Lepidium meyenii) and Stevia (Eupium). The external preparation for skin according to (3), wherein one or more selected from rebaudianum) is selected .

  ADVANTAGE OF THE INVENTION According to this invention, the technique which fully raises the melanin production inhibitory effect of ascorbic acids can be provided.

(1) Ascorbic acids as essential components of the external preparation for skin of the present invention The external preparation for skin of the present invention is characterized by containing ascorbic acid and / or a derivative thereof. Ascorbic acid derivatives that can be used in the external preparation for skin of the present invention include ascorbic acid salts, ascorbic acid phosphates and salts thereof, ascorbic acid glycosides such as ascorbic acid-2-glucoside and salts thereof Etc. can be suitably exemplified. These salts can be used without particular limitation as long as they are usually used in quasi drugs, cosmetics, skin external medicines, etc., for example, alkali metal salts such as sodium salts and potassium salts Preferred examples include alkaline earth metal salts such as calcium and magnesium, organic amine salts such as ammonium salt, triethanolamine salt and triethylamine salt, and basic amino acid salts such as lysine salt and arginine salt. In the skin external preparation of the present invention, such a salt may contain only one species or may contain two or more species in combination. In the external preparation for skin of the present invention, ascorbic acid and a derivative thereof are preferably ascorbic acid-2-glucoside and / or a salt thereof. The preferable content of such ascorbic acid and / or a derivative thereof in the external preparation for skin of the present invention is 0.1 to 10% by mass, more preferably 1 to 10% by mass based on the total amount of external preparation for skin. 5% by mass. This is because if the amount is too small, the inhibitory action of ascorbic acid on melanin production may be impaired, and if it is too large, the effect may reach its peak.

(2) Centaureidine which is an essential component of the external preparation for skin of the present invention The external preparation for skin of the present invention contains centauridine and / or a salt thereof in an amount of 0.001 to 1% by mass as an essential component. And Centaureidine is an isoflavanone that is contained in a very small amount throughout the plants of the family Asteraceae. , Russian cornflower (Acroptilon repens), yacon (Smallanthus sonchifolius), maca (Lepidium meyenii) or stevia (Eupatorium rebaudianum). According to the inventor's examination, the content ratio is 1 to 3 mg per 1 kg of the plant body. In order to obtain a fraction containing centaureidine in an amount suitable for the skin external preparation of the present invention from these plant bodies, the plants of the family Asteraceae are extracted using an alcohol such as ethanol or isopropanol as a solvent, and extracted with alcohol. After removing the solvent from this, the residue was liquid-liquid extracted with ethyl acetate and water, the ethyl acetate phase was taken, concentrated, and fractionated and purified by column chromatography using silica gel as a carrier. Can be preferably exemplified. In the alcohol extraction, 1 to 20 parts by mass of a solvent is added to 1 part by mass of a plant or a processed product obtained by chopping it, and it is several days at room temperature, several hours at a temperature near the boiling point, as desired. Then, after stirring, removing the insoluble material by filtration or the like, the solution may be concentrated by distillation under reduced pressure or the like. Such a solvent-removed product of the extract contains 0.0003 to 0.003% by mass of centerureidine. The solvent-removed product of the extract is subjected to liquid-liquid extraction with ethyl acetate and water, and the ethyl acetate phase is taken. A fraction can be obtained. Further, this was charged into a column packed with silica gel and eluted with chloroform, a mixture of chloroform and methanol (chloroform: methanol = 99: 1 → 70: 30) while fractionating 1 ml at a time. Confirmation by chromatography, silica gel thin layer chromatography, using a developing solvent as chloroform, collecting fractions of spots with Rf of about 0.15, and distilling off the solvent, containing 8-15% by mass of centaureidine The fraction to be obtained is obtained. The amount of centauridine in the fractionation was determined by HPLC (ODS column 4.6 mm × 150 mm, column temperature 40 ° C., elution solvent 40% acetonitrile aqueous solution, flow rate 1 ml / min, detection UV 220 nm) using a standard substance. It can be quantified by the line method. A production example is shown below.

<Production Example 1>
Shred 5 kg of the dried product above the ground of the Yarrow, add 10 l of ethanol, heat and reflux for 3 hours with stirring, cool to room temperature, filter to remove insolubles, concentrate under reduced pressure, 527 g of extract was obtained. When this product was analyzed by HPLC, it was found to contain 0.019% by mass of centerureidine. To this, 2 l of ethyl acetate and 2 l of water were added, liquid-liquid extraction was performed, the ethyl acetate phase was removed and distilled under reduced pressure, and the residue was subjected to silica gel column chromatography (chloroform, chloroform / methanol mixed solution as an elution solvent). As a result of purification, 7.8 g of amorphous containing 12% by mass of centerureidine was obtained.

<Production Example 2>
The yarrow was changed to cornflower and treated in the same manner as in Production Example 1 to obtain 2.5 g of amorphous containing 14% by mass of center ureidine.

<Production Example 3>
The yarrow was changed to tansy and treated in the same manner as in Production Example 1 to obtain 1.1 g of amorphous containing 11% by mass of center ureidine.

<Production Example 4>
The yaw was changed to Russian cornflower and treated in the same manner as in Production Example 1 to obtain 0.9 g of amorphous containing 15% by mass of center ureidine.

<Production Example 5>
The yak was changed to yacon rhizome and treated in the same manner as in Production Example 1 to obtain 1.3 g of amorphous containing 10% by mass of center ureidine.

<Production Example 6>
The yaw was changed to stevia rhizome and treated in the same manner as in Production Example 1 to obtain 1.6 g of amorphous containing 9% by mass of center ureidine.

(3) External preparation for skin of the present invention The external preparation for skin of the present invention contains the above-mentioned essential components, enhances the melanin production inhibitory action of ascorbic acids, and has the action of significantly preventing and improving pigment abnormalities associated with inflammation. Further, as a secondary effect, an increase in the amount of transdermal water dispersion is suppressed after inflammation has subsided or pigment abnormality has been improved. That is, the appearance of rough skin after inflammation is suppressed. The topical skin preparation of the present invention contains one or more selected from glycyrrhizic acid, alkyl glycyrrhetinate, and salts thereof because the effects of the present invention can be made clearer. It is preferable. Such an ingredient is an ingredient known as an quasi-drug active ingredient, and glycyrrhizic acid and / or a salt thereof is preferably dipotassium glycyrrhetinate, and alkyl glycyrrhetinate and / or a salt thereof is stearyl glycyrrhetinate. Is preferred. The preferable content of this component is 0.05 to 0.5% by mass with respect to the total amount of the external preparation for skin. By containing this, when the topical skin preparation of the present invention is administered immediately after sunburn or the like, the inflammation is suppressed more quickly, the prognosis is improved, and the preventive effect of deterioration such as pigmentation is increased. .

  In the external preparation for skin of the present invention, in addition to the above-mentioned components, optional components that are usually used in cosmetics and external preparations for skin can be contained. Examples of such optional ingredients include macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, and hardened coconut oil. Oils such as hardened oil, mole, hardened castor oil, beeswax, candelilla wax, carnauba wax, ibotarou, lanolin, reduced lanolin, hard lanolin, jojoba wax, waxes, liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum , Hydrocarbons such as microcrystalline wax, higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid, cetyl alcohol, stearyl alcohol, isostearyl Alcohol, behenyl alcohol, octyldodecanol, higher alcohol such as myristyl alcohol, cetostearyl alcohol, cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, di-2-ethylhexyl sebacate, cetyl lactate, malic acid Diisostearyl, di-2-ethylhexanoic acid ethylene glycol, dicaprate neopentyl glycol, di-2-heptylundecanoic acid glycerin, tri-2-ethylhexanoic acid glycerin, tri-2-ethylhexanoic acid trimethylolpropane, tri Synthetic ester oils such as trimethylolpropane isostearate and pentane erythritol tetra-2-ethylhexanoate, dimethylpolysiloxane, methylphenylpoly Loxane, linear polysiloxane such as diphenylpolysiloxane, cyclic polysiloxane such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexanesiloxane, amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, Oil agents such as silicone oil such as modified polysiloxane such as fluorine-modified polysiloxane, anionic surfactants such as fatty acid soap (sodium laurate, sodium palmitate, etc.), potassium lauryl sulfate, triethanolamine ether of alkyl sulfate, chloride Cationic surfactants such as stearyltrimethylammonium, benzalkonium chloride, laurylamine oxide, imidazoline-based amphoteric surfactants (2-cocoyl-2-imida Zolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine surfactants (alkyl betaine, amide betaine, sulfobetaine, etc.), amphoteric surfactants such as acylmethyltaurine, sorbitan fatty acid esters (sorbitan) Monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (eg, glyceryl monostearate), propylene glycol fatty acid esters (eg, propylene glycol monostearate), hardened castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid ester Tells (POE-glycerol monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE2-octyldodecyl ether, etc.), POE alkylphenyl ethers (POE nonylphenyl) Ethers, etc.), Pluronic types, POE / POP alkyl ethers (POE / POP2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), Nonionic surfactants such as sucrose fatty acid ester and alkyl glucoside, polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene Polyols such as recall, dipropylene glycol, diglycerin, isoprene glycol, 1,2-pentanediol, 2,4-hexylene glycol, 1,2-hexanediol, 1,2-octanediol, pyrrolidone carboxylic acid Moisturizing ingredients such as sodium, lactic acid, sodium lactate, guar gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, xanthan gum, curdlan, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylhydroxypropylcellulose, chondroitin sulfate , Dermatan sulfate, glycogen, heparan sulfate, hyaluronic acid, sodium hyaluronate, tragacanth gum, keratan sulfate, chondroitin, mucoitin sulfate, hyaluronan Droxyethyl guar gum, carboxymethyl guar gum, dextran, keratosulfuric acid, locust bean gum, succinoglucan, caronic acid, chitin, chitosan, carboxymethylchitin, agar, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, Thickeners such as polyethylene glycol and bentonite, surface may be treated, powder such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, silicic anhydride (silica), aluminum oxide, barium sulfate The surface may be treated, bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, bitumen, titanium oxide, zinc oxide inorganic pigments, the surface may be treated, mica titanium, Fish phosphorus foil, bismuth oxychloride Pearl agents, which may be raked Red 202, Red 228, Red 226, Yellow 4, Blue 404, Yellow 5, Red 505, Red 230, Red 223, Orange 201 No., Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204 and other organic dyes, polyethylene powder, polymethyl methacrylate, nylon powder, organopolysiloxane elastomer Organic powders such as paraaminobenzoic acid UV absorbers, anthranilic acid UV absorbers, salicylic acid UV absorbers, cinnamic acid UV absorbers, benzophenone UV absorbers, sugar UV absorbers, 2- ( 2′-hydroxy-5′-t-octylphenyl) benzotriazole, 4-methoxy-4′-t-butyldibenzoylmethane, etc. External line absorbers, lower alcohols such as ethanol and isopropanol, vitamin A or its derivatives, vitamin B6 hydrochloride, vitamin B6 tripalmitate, vitamin B6 dioctanoate, vitamin B2 or its derivatives, vitamin B12, vitamin B15 or its derivatives, etc. Vitamin E such as vitamin B, α-tocopherol, β-tocopherol, γ-tocopherol, vitamin E acetate, vitamin D, vitamin H, pantothenic acid, panthetin, pyrroloquinoline quinone, and the like can be preferably exemplified . The skin external preparation of this invention can be manufactured by processing these according to a conventional method.

  The external preparation for skin of the present invention thus obtained has a higher melanin production inhibitory action possessed by ascorbic acids, and can also improve pigment abnormalities that occur after inflammation. The external preparation for skin of the present invention can be applied to both cosmetics including quasi-drugs and external preparations for skin, but ascorbic acids are effective ingredients as components that exhibit melanin production inhibitory action of quasi-drugs. Since it is classified, it is preferably applied to quasi drugs. This is because a form in which a use form in a quasi-drug is clearly displayed and used in a situation in which the user is clearly aware of the use form is particularly preferable for the expression of the effect. In addition, when it contains one or more selected from glycyrrhizic acid, alkyl glycyrrhetinate and salts thereof, it has the characteristics as an active ingredient of quasi drugs resulting from these anti-inflammatory effects. It is also possible to use it as a quasi-drug with anti-inflammatory action. That is, the external preparation for skin of the present invention has an indication that it is a quasi-drug that has an action of suppressing melanin production and / or an action of suppressing inflammation, and an appropriate amount in the method of use. Incorporate it into a cut cotton etc. in a site that is worried about spots or pigmentation, or a site that is slightly inflamed, lightly rub it, apply it by pressing, A quasi-drug with indications to improve stains and pigmentation, or to reduce inflammation, and to stop use immediately if you feel irritation or burning due to the above operation It is preferable to apply to.

  EXAMPLES Hereinafter, the present invention will be described in more detail with reference to examples, but it goes without saying that the present invention is not limited to these examples.

  In accordance with the formulation shown below, a quasi-drug (milky lotion) that is an external preparation for skin of the present invention was prepared. That is, weigh each component of A, B and C, heat to 80 ° C., gradually add B to the emulsified with stirring, emulsify, then add C to neutralize, cool with stirring, and cool emulsion 1 Obtained.

I)
Behenyl alcohol 0.5% by mass
Cetyl isooctanoate 2% by mass
Squalane 8% by mass
Dimethicone 2% by mass
Sorbitan sesquistearate 1.5% by mass
POE (45) stearic acid 1% by mass
Cetyl stearate 0.5% by mass
Behenic acid 0.5% by mass
Stearyl glycyrrhetinate 0.1% by mass
B)
1,3-butanediol 5% by mass
Glycerin 5% by mass
1,2-pentanediol 5% by mass
50% by weight of water
Ascorbic acid-2-glucoside 2% by mass
Carboxyvinyl polymer 0.3% by mass
Amorphous of Production Example 1 0.5% by mass
(Centaureidine 0.06% by mass)
C)
17.5% by weight of water
Potassium hydroxide 0.6% by mass

<Test Example 1>
About the emulsion 1, the panelists of 5 persons were used and the pigmentation inhibitory effect was investigated. In other words, five 2 cm × 3 cm sites were created on the back, irradiated with ultraviolet rays (light source: SE lamp) three times the MED (minimum erythema formation dose) determined in advance, and the specimen was exposed 5 minutes after irradiation. Applied. Thereafter, application was performed once a day for a total of 14 times. As specimens, emulsion 1, comparative example 1 in which ascorbic acid-2-glucoside in emulsion 1 was replaced with water, and comparative example 2 in which amorphous in production example 1 of emulsion 1 was replaced with water were used. In addition, there were provided an irradiation control in which only irradiation was performed and an untreated control in which neither irradiation nor sample administration was performed. Seven days after the final treatment, site color and transcutaneous dissipated water (TEWL) were measured. The results are shown in Table 1. The color difference was measured as a ΔL value with respect to the site of the untreated control.

  The crude drug extract fraction containing the center ureidine of the emulsion 1 was changed, and the emulsions 2 to 6 were prepared in the same manner as in Example 1, and the test was carried out using the back of five persons as in Test Example 1. The results are shown in Table 2. From this, it can be seen that the same effect can be obtained if any of the crude drug extract fractions contains a prescribed amount of center ureidine.

I)
Behenyl alcohol 0.5% by mass
Cetyl isooctanoate 2% by mass
Squalane 8% by mass
Dimethicone 2% by mass
Sorbitan sesquistearate 1.5% by mass
POE (45) stearic acid 1% by mass
Cetyl stearate 0.5% by mass
Behenic acid 0.5% by mass
Stearyl glycyrrhetinate 0.1% by mass
B)
1,3-butanediol 5% by mass
Glycerin 5% by mass
1,2-pentanediol 5% by mass
50% by weight of water
Ascorbic acid-2-glucoside 2% by mass
Carboxyvinyl polymer 0.3% by mass
Ingredients in Table 2 0.5% by mass
C)
17.5% by weight of water
Potassium hydroxide 0.6% by mass

  According to the prescription shown below, the amount of the crude drug extract fraction containing the center ureidine of emulsion 1 was changed, and emulsions 7 and 8 were prepared in the same manner as in Example 1, and the backs of 5 people were used in the same manner as in Test Example 1. The test was conducted. The results are shown in Table 3. From this, it can be seen that the content of center ureidine is required to be 0.001% by mass or more.

(Emulsion 7)
I)
Behenyl alcohol 0.5% by mass
Cetyl isooctanoate 2% by mass
Squalane 8% by mass
Dimethicone 2% by mass
Sorbitan sesquistearate 1.5% by mass
POE (45) stearic acid 1% by mass
Cetyl stearate 0.5% by mass
Behenic acid 0.5% by mass
Stearyl glycyrrhetinate 0.1% by mass
B)
1,3-butanediol 5% by mass
Glycerin 5% by mass
1,2-pentanediol 5% by mass
50% by weight of water
Ascorbic acid-2-glucoside 2% by mass
Carboxyvinyl polymer 0.3% by mass
Amorphous of Production Example 1 0.001% by mass
(Center uredin 0.00012% by mass)
C)
Water 17.999 mass%
Potassium hydroxide 0.6% by mass

(Emulsion 8)
I)
Behenyl alcohol 0.5% by mass
Cetyl isooctanoate 2% by mass
Squalane 8% by mass
Dimethicone 2% by mass
Sorbitan sesquistearate 1.5% by mass
POE (45) stearic acid 1% by mass
Cetyl stearate 0.5% by mass
Behenic acid 0.5% by mass
Stearyl glycyrrhetinate 0.1% by mass
B)
1,3-butanediol 5% by mass
Glycerin 5% by mass
1,2-pentanediol 5% by mass
50% by weight of water
Ascorbic acid-2-glucoside 2% by mass
Carboxyvinyl polymer 0.3% by mass
Amorphous 0.01% by mass of Production Example 1
(Centaureidine 0.0012% by mass)
C)
17.99% by mass of water
Potassium hydroxide 0.6% by mass

  According to the prescription shown below, ascorbic acid-2-glucoside of emulsion 1 was changed to disodium ascorbate phosphate, and emulsion 9 was prepared in the same manner as in Example 1, and using the back of 5 persons as in Test Example 1. A test was conducted. The results are shown in Table 4. From this, it can be seen that the effects of the present invention can be obtained even with disodium ascorbate phosphate.

I)
Behenyl alcohol 0.5% by mass
Cetyl isooctanoate 2% by mass
Squalane 8% by mass
Dimethicone 2% by mass
Sorbitan sesquistearate 1.5% by mass
POE (45) stearic acid 1% by mass
Cetyl stearate 0.5% by mass
Behenic acid 0.5% by mass
Stearyl glycyrrhetinate 0.1% by mass
B)
1,3-butanediol 5% by mass
Glycerin 5% by mass
1,2-pentanediol 5% by mass
50% by weight of water
Ascorbic acid disodium 2 mass%
Carboxyvinyl polymer 0.3% by mass
Amorphous of Production Example 1 0.5% by mass
(Centaureidine 0.06% by mass)
C)
17.5% by weight of water
Potassium hydroxide 0.6% by mass

  The present invention can be suitably applied to quasi-drugs for prevention and improvement of pigmentation due to sunburn or the like.

Claims (4)

A skin external preparation characterized by containing 1) ascorbic acid and / or a derivative thereof, and 2) 0.001 to 1% by mass of centerureidine and / or a salt thereof .   The said ascorbic acid and / or its salt are 1 type (s) or 2 or more types selected from ascorbic acid phosphate ester, ascorbic acid-2-glucoside, and its salt, The Claim 1 characterized by the above-mentioned. Topical skin preparation.   The center ureidine is derived from the alcoholic extract of an Asteraceae plant liquid-liquid extracted with ethyl acetate and water, concentrated in the ethyl acetate phase, and fractionated and purified by column chromatography using silica gel as a carrier. The external preparation for skin according to claim 1 or 2, wherein   The Asteraceae plants include Yarrow (Achilea millefolium), Cornflower (Centaurea cyanus), Tansy (Tanacetum parthenium), Russian cornflower (Acroptilon repens), Yacon (Smallanthus sonchifolius), Maca (Lepidium meyenii) and Stevia (Eupatorium reu) The external preparation for skin according to claim 3, wherein one or more selected are used.